The Calcium Sensitizer Levosimendan Improves Human Diaphragm Function

Jonne Doorduin1, Christer A. Sinderby2,3, Jennifer Beck3,4, Dick F. Stegeman5,6, Hieronymus W. H. van Hees7, Johannes G. van der Hoeven1, and Leo M. A. Heunks1

1Department of Critical Care Medicine, Radboud University Nijmegen Medical Centre, The Netherlands; 2Department of Medicine, Division of Critical Care Medicine, University of Toronto; 3Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, University of Toronto; 4Department of Pediatrics, St. Michael’s Hospital, University of Toronto, Toronto, Canada; 5Department of Neurology, Radboud University Nijmegen Medical Centre, The Netherlands; 6Faculty of Human Movement Sciences, Research Institute MOVE, VU University, Amsterdam, The Netherlands; and 7Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Originally Published in Press as DOI: 10.1164/rccm.201107-1268OC on September 29, 2011

Copyright 2012 by the American Thoracic Society

Am J Respir Crit Care Med Vol 185, Iss. 1, pp 90–95, Jan 1, 2012

Correspondence and requests for reprints should be addressed to Leo Heunks, M.D., Ph.D., Radboud University Nijmegen Medical Centre, Department of Critical Care Medicine, Geert Grooteplein zuid 10, 6525 GA Nijmegen, The Netherlands. E-mail: L.Heunks@ic.umcn.nl

This article has an online supplement, which is accessible from this issue’s table of contents at www.atsjournals.org

Received in original form July 14, 2011; accepted in final form September 13, 2011

Supported by institutional resources.


What This Study Adds to the Field

We report that the calcium sensitizer levosimendan improves neuromechanical efficiency of the human diaphragm. In addition, levosimendan restored the loss of diaphragm contractility after an intervention of loaded breathing. These findings suggest that levosimendan treatment may be an effective strategy to improve muscle function in patients with respiratory muscle weakness.

AT A GLANCE COMMENTARY

Scientific Knowledge on the Subject

Respiratory muscle weakness frequently occurs in chronic diseases and contributes to morbidity and mortality. There is no specific pharmacological treatment available to improve respiratory muscle function in patients with impending respiratory muscle failure. Previous studies have demonstrated that calcium sensitizers improve in vitro function of the respiratory muscles.

Diaphragm dysfunction in these disorders is multifactorial and includes muscle fiber atrophy and contractile protein dysfunction (3, 8–11). We found that diaphragm muscle fibers of patients with COPD display reduced sensitivity of the contractile proteins to calcium (9, 12). In other words, more calcium is needed to develop the same amount of force as in the non-COPD diaphragm, resulting in impaired contractile efficiency of the diaphragm muscle. Subsequent studies have shown that calcium sensitivity is also reduced in the diaphragm of animal models of congestive heart failure and prolonged mechanical ventilation (2, 13). Despite a better understanding of respiratory muscle dysfunction in chronic diseases, no drug is available to improve respiratory muscle function in humans.

Levosimendan is a clinically used calcium sensitizer that has been approved to enhance cardiac contractility in patients with acute heart failure. Clinical studies have shown that levosimendan improves cardiac function in these patients (14). Levosimendan enhances the binding of calcium to troponin C, thereby improving the responsiveness of myofilaments to calcium. Accordingly, a greater amount of force is generated for the same level of cytosolic calcium, resulting in enhanced contractile efficiency. Levosimendan has vasodilatory properties mediated by the opening of the ATP-sensitive potassium (KATP) channels (15).

Recently, we have shown that levosimendan enhances calcium sensitivity of permeabilized muscle fibers obtained from the human diaphragm, including patients with COPD (12). However, the effects of calcium sensitizing on the human diaphragm in vivo have not been studied. Based on our in vitro data (12), we
hypothetize that levosimendan improves contractile function of the human diaphragm in vivo through calcium sensitizing and that levosimendan would decrease muscle fiber conduction velocity of the diaphragm through its effects on K_ATP channels in diaphragm fibers. We tested this hypothesis in a double-blind, placebo-controlled, crossover design in healthy subjects performing inspiratory loading tasks. Some of the results of this study have been previously reported in the form of an abstract (16).

METHODS

We enrolled 30 healthy volunteers in this trial. The protocol was approved by the ethical committee of the Radboud University Nijmegen Medical Centre and registered at ClinicalTrials.gov (NCT01101620). All subjects gave their informed consent.

Esophageal Catheter

Diaphragm electromyographic activity (EMGdi), esophageal pressure (Pes), and gastric pressure (Pga) were obtained with a multielectrode esophageal catheter with two balloons (details are provided in the online supplement). Transdiaphragmatic pressure (Pdi) was calculated as Pga − Pes.

Magnetic Stimulation and Maximal Inspiratory Effort

Cervical magnetic stimulation of the phrenic nerves was performed to measure twitch Pdi (Pdi_tw) and compound muscle action potential of the diaphragm (CMAPdi). Details about the stimulation protocol are provided in the online supplement.

Maximal voluntary Pdi (Pdi_max) was measured as mean Pdi in the first second during a maximal inspiratory effort against a closed valve at functional residual capacity.

Inspiratory Loading Task

Each subject performed two identical loading tasks, one before and one after administration of the study medication. Sitting in upright position with uncast abdomen, subjects breathed through a mouthpiece while wearing a nose clip. Subjects performed intermittent inspiratory maneuvers of 10 seconds against a closed valve (near-isometric contractions) followed by 7 seconds of unloaded breathing. Duty cycle was imposed by a sound signal, and subjects were asked to target 40% of Pdi_max. Visual feedback of Pdi was provided. Total loading task duration was 10 minutes. During loading, EMGdi and Pdi were recorded continuously, as well as in unloaded conditions approximately 5 minutes before and after loading. Respiratory effort sensation was scored with a Borg scale (range, 6–20) at 1, 3, 6, and 9 minutes into loading.

Experimental Protocol

The protocol is presented in Figure 1. Pdi_tw and Pdi_max were measured and followed by the first loading task and 30 minutes of unloaded breathing. After randomization, subjects received levosimendan bolus (40 μg/kg bodyweight, intravenously) or an equal volume of placebo in 10 minutes. Pdi_tw and Pdi_max measurements were repeated and followed by 30 minutes of continuous levosimendan (0.1 μg/kg bodyweight/min, intravenously) or placebo infusion. A second loading task was performed while infusing levosimendan (0.2 μg/kg/min, intravenously) or placebo.

Heart rate, end tidal carbon dioxide (etCO₂), and peripheral oxygen saturation (SpO₂) were monitored continuously. Blood pressure was measured noninvasively every 10 minutes and during bolus administration each minute. In six subjects, cardiac output was determined by transthoracic echocardiography directly before and after bolus administration.

Data Analysis and Statistics

Measurement variables were analyzed offline in Matlab R2009b (The Mathworks, Natick, MA) (details are provided in the online supplement). The ratio of mean inspiratory Pdi and EMGdi amplitude was calculated as a measure of the neuromechanical efficiency of the diaphragm. Changes in muscle fiber conduction velocity were evaluated using the power spectrum center frequency (CFdi) of the EMGdi (details are provided in the online supplement). Comparisons were made with the appropriate t test. Changes over time during loaded breathing were analyzed using repeated measures ANOVA. Values are means ± SEM, and P < 0.05 was considered significant. Statistical analyses were performed with SPSS 16.0 (SPSS, Chicago, IL).

RESULTS

Baseline characteristics of the subjects (male/female, 23/7; age, 22 ± 0.4 yr; bodyweight, 74 ± 1 kg; and body mass index, 23 ± 0.4 kg/m²) were not different between the placebo and levosimendan groups. All subjects (n = 30) received study medication as dictated by the protocol. One subject was excluded due to technical problems with the esophageal catheter. Two subjects were not able to maintain targeted Pdi (<30% of Pdi_max) during the first loading task and were excluded from data analysis. The remaining subjects (placebo, n = 13; levosimendan, n = 14) were able to keep their targeted Pdi during both loading tasks (44 ± 1% and 43 ± 2%), indicating compliance to the protocol. SpO₂ was above 96% in all subjects during the study; no supplemental oxygen was given. There were no differences in etCO₂ between the placebo and levosimendan group during loaded breathing.

Furthermore, there were no serious adverse events during the experimental protocol. One subject, receiving levosimendan, experienced a mild degree of nausea after completion of the study.

Diaphragm Contractility

Cervical magnetic stimulation of the phrenic nerves resulted in reproducible twitch pressures in all subjects. Data from magnetic stimulation and maximal inspiratory maneuvers, as well as hemodynamic data, are given in Table 1. There was no significant difference in Pdi_tw and Pdi_max between the placebo and the levosimendan groups before study medication.

Figure 2 shows a decreased contractile response of the diaphragm after the first loading task in a subject receiving placebo.
On average, loaded breathing in subjects receiving placebo resulted in significant reductions in Pdi_{tw} (−9 ± 3%; P = 0.01) and Pdi_{max} (−5 ± 3%; P < 0.05). The group receiving levosimendan after the first period of loaded breathing revealed no significant decrease in Pdi_{tw} and Pdi_{max} (Figure 3; Table 1).

Neuromechanical Efficiency of the Diaphragm

In Figure 4, representative tracings of EMG_{di} and Pdi are presented for the first loading task (before study medication) and the second loaded task (with and after study medication) for both groups. Neuromechanical efficiency of the diaphragm (Pdi/EMG_{di}) in the first loading task was not different between the placebo and the levosimendan groups (both 1.3 ± 0.2 cm H_{2}O/μV) and remained stable throughout the loading task (Figure 5). Neuromechanical efficiency during unloaded breathing and during the second loading task was improved by 21% (P < 0.05, compared with the first loading task) in the levosimendan group, whereas neuromechanical efficiency was not affected in the placebo group (Figure 5). The improved neuromechanical efficiency in subjects receiving levosimendan sustained throughout the entire loading task.

Center Frequency of Diaphragm Electrical Activity

During both loaded breathing protocols, CFdi decreased over time (P < 0.001) (see Figure E1 in the online supplement) in both groups. Administration of levosimendan resulted in a downward shift in baseline CFdi during the second loaded breathing protocol (P < 0.05; Figure E1), whereas placebo did not affect CFdi.

Respiratory Effort Sensation

Respiratory effort sensation increased over time (P < 0.001) during loaded breathing until a score of 16 was reached. Neither levosimendan nor placebo affected respiratory effort sensation.

**DISCUSSION**

The present study is the first to evaluate the effect of the calcium sensitizer levosimendan on human diaphragm function *in vivo*. In this double-blind, randomized study, an intervention of loaded breathing resulted in significant loss of diaphragm contractility in the placebo group but not in the levosimendan group, suggesting that levosimendan restored diaphragm contractility. Loaded breathing after drug administration was associated with improved neuromechanical efficiency of the diaphragm in the levosimendan group. Furthermore, levosimendan reduced baseline center frequency of diaphragm electrical activity. Levosimendan was well tolerated with negligible side effects.

**Calcium Sensitivity and Muscle Fiber Conduction Velocity: Effects of Levosimendan**

Skeletal muscle force develops as intracellular calcium rises and binds to troponin C, resulting in conformational changes in the troponin complex, allowing interaction between actin and myosin to form force-generating cross-bridges. Reuptake of calcium from the cytoplasm into the sarcoplasmic reticulum is a high energy-consuming process (up to 40% of total energy expenditure). Thus, reduced sensitivity of the troponin complex for calcium requires higher levels of cytoplasmic calcium to generate the same amount of force, requiring higher energy consumption and elevated CO_{2} production.

Levosimendan belongs to a relatively new class of drugs, the calcium sensitizers and is approved in more than 40 countries worldwide to improve cardiac function in patients with acute heart failure (14). Although the loading dose of levosimendan in this study is higher than recommended for the treatment of heart failure, Levosimendan's effects on diaphragm function and neuromechanical efficiency are promising for future studies.

**TABLE 1. DIAPHRAGM CONTRACTILITY AND HEMODYNAMIC VARIABLES AT BASELINE AND AFTER LOADING + BOLUS ADMINISTRATION**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Placebo (n = 13)</th>
<th>Levosimendan (n = 14)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>After Loading + Bolus Administration</td>
</tr>
<tr>
<td>Diaphragm contractility*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pdi_{max}, cm H_{2}O</td>
<td>35 ± 2^{1}</td>
<td>32 ± 2^{1}</td>
</tr>
<tr>
<td>CMAP_{di}, mV</td>
<td>1.3 ± 0.2</td>
<td>1.3 ± 0.2</td>
</tr>
<tr>
<td>Pdi_{max}, cm H_{2}O</td>
<td>130 ± 8</td>
<td>122 ± 7^{2}</td>
</tr>
<tr>
<td>EMG_{di max}, μV</td>
<td>76 ± 9</td>
<td>81 ± 10</td>
</tr>
<tr>
<td>Hemodynamic variables^{1}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAP, mm Hg</td>
<td>92 ± 2</td>
<td>89 ± 4</td>
</tr>
<tr>
<td>HR, bpm</td>
<td>71 ± 3</td>
<td>73 ± 3</td>
</tr>
<tr>
<td>CO L/min</td>
<td>4.5 ± 1.3</td>
<td>4.6 ± 0.4</td>
</tr>
</tbody>
</table>

*Significantly different from before study medication (P < 0.05).

^{1} Data are presented as mean ± SEM.

^{2} MAP, HR, and CO were measured directly before and after bolus administration. CO was measured only in n = 2 (placebo group) and n = 4 (levosimendan group).

Definition of abbreviations: CMAP_{di} = compound muscle action potential of the diaphragm; CO = cardiac output; EMG_{di max} = maximum electromyographic activity; MAP = mean arterial pressure; Pdi_{max} = maximum transdiaphragmatic pressure; Pdi_{tw} = twitch transdiaphragmatic pressure; HR = heart rate.

^{*} Pdi_{tw}, CMAP_{di}, Pdi_{max}, and EMG_{di max} were measured before the first loading task and after bolus administration of study medication.

**Figure 2.** (A) The compound muscle action potential of the diaphragm (CMAP_{di}) and (B) twitch transdiaphragmatic pressure (Pdi_{tw}) elicited by cervical magnetic stimulation before (black line) and after the first loading task (blue striped line) in a subject receiving placebo. In response to equal diaphragm activation (i.e., equal CMAP_{di}), there is decreased contractility after loaded breathing. Note the difference in scale of the x axis between panels A and B.
Acute action of levosimendan on respiratory muscle contractility

**Clinical Implications**

Reduced force generation of the respiratory muscles has been demonstrated in numerous disorders, including COPD, congestive heart failure, pulmonary hypertension, and patients on mechanical ventilation (1-7). There are no pharmacological interventions available to improve respiratory muscle function.

Aubier and colleagues have previously shown that dopamine (26) and aminophylline (27) improve contractility of the human diaphragm, although the effects of aminophylline are controversial (28). Neither dopamine nor aminophylline has been used in clinical practice to optimize respiratory muscle function, probably due to the small therapeutic window, the risk of side effects (aminophylline, dopamine), and the very short half-life (dopamine). Instead, the active levosimendan metabolite OR-1896 has a half-life of 70 to 80 hours, resulting in clinical effect up to 1 week after 24-hour infusion (29). More importantly, both aminophylline and dopamine improve contractility by elevating intracellular calcium concentration, resulting in an increased ATP utilization. As discussed elsewhere (12), inorganic phosphate accumulation contributes to the development of muscle fatigue and depresses calcium sensitivity (30). In addition, elevated energy expenditure increases CO₂ production, requiring a higher level of ventilation. This limits the clinical utility of these drugs for the improvement of respiratory muscle function in patients with imminent ventilatory failure. Rather, calcium sensitizers improve muscle contractility without elevating energy expenditure (31). In addition, more efficient breathing may hasten liberation from mechanical ventilation (32). This may be important for patients with respiratory failure, such as acute exacerbation of COPD. Of note, our previous in vitro work showed that the effect of levosimendan is more profound in type-1 diaphragm fibers than in type-2 fibers (12). Because a fiber type shift toward type-1 fibers is known to occur in the diaphragm of patients with COPD (8) and congestive heart failure (33), levosimendan treatment can potentially be more effective in these patients than in healthy subjects. Accordingly, the rationale for evaluating the effect of levosimendan on respiratory muscle function in patients with respiratory failure appears highly appropriate.

**Experimental Model**

The contractile performance of the diaphragm was evaluated using magnetic stimulation and maximal inspiratory efforts.
and thus increased neuromechanical efficiency of the diaphragm. The subject receiving levosimendan shows decreased neural activation compared to the placebo, there is no change in EMGdi (i.e., neural activation), whereas the subject receiving levosimendan shows decreased neural activation and thus increased neuromechanical efficiency of the diaphragm.

Magnetic stimulation has a clear benefit over voluntary maneuvers because it is effort independent and highly reproducible (34). Values for Pdiw and Pdimax reported in our study are similar to those reported by other groups for healthy subjects (20, 35). Due to coincidence, baseline Pdiw and CMAPdi amplitude were lower (though insignificant) in the levosimendan group (Table 1), suggesting these subjects were more difficult to stimulate. Correcting for CMAPdi amplitude abolished the baseline difference between the groups (data not shown).

To further evaluate the function of the diaphragm, we measured neuromechanical efficiency of the diaphragm (Pdi/EMGdi) during inspiratory loaded breathing. We found that diaphragm neuromechanical efficiency at 40% of Pdimax was constant over time and that CFdi decreased over time during loaded breathing, which are in line with previous data from Sinderby and colleagues (36). We also found that, despite evidence of twitch force loss, the diaphragm neuromechanical efficiency was not reduced in the placebo group during the second loaded breathing task. Thus, the reductions in maximal contractility were not reflected in the neuromechanical efficiency during submaximal contractions. Regardless of the reason for this inconsistency, the double-blinded randomized design of the study should ensure that the finding of improved neuromechanical efficiency, which occurred only in the levosimendan group, was not due to bias, carry-over effects, or other subjective influences.

For an accurate physiological measurement of EMGdi and CFdi during voluntary breathing, it is necessary to control for changes in muscle-to-electrode distance, electrode positioning with respect to the muscle fiber direction and location, influence of cross-talk from other muscles (including the heart and the esophagus), and electrode movement–induced artifacts. The technology used to measure and process the EMGdi and CFdi in our study minimizes these influences (37, 38).

It could be postulated that improved contractile function of the diaphragm resulted from the cardiac inotropic effects of levosimendan. However, subjects in the present study did not have a medical history of cardiac disease, and the effect of levosimendan on cardiac output was modest. Development of Pdiw occurs through a sharp anaerobic maneuver of the diaphragm; therefore, it is unlikely that an improved cardiac output (and oxygen delivery) would explain the restored diaphragm contractility with levosimendan. Moreover, levosimendan improved efficiency already during unloaded breathing and immediately at the start of the loading task, which is unlikely to be the result of improved oxygen delivery to the diaphragm.

The dosage of levosimendan used in the current study was derived from earlier studies in healthy subjects that demonstrated limited side effects (39). This is in line with our study. Future studies should evaluate the effects of lower doses of levosimendan on respiratory muscle function in humans.

In conclusion, the present study demonstrates that the calcium sensitizer levosimendan improves contractile function and neuromechanical efficiency of the human diaphragm. These findings suggest a new therapeutic approach for patients with acute respiratory muscle dysfunction.

Author disclosures are available with the text of this article at www.atsjournals.org.

Acknowledgment: The authors thank Dr. M. Kivikko and Prof. P. Rytila from Orion Pharma, Espoo, Finland, for providing levosimendan and placebo; N. Comtois from the Department of Medicine, Division of Critical Care Medicine, St. Michael’s Hospital, University of Toronto, Canada and Dr. H. van Dijk from the Department of Neurology, Radboud University Nijmegen Medical Centre, for technical assistance; J. van den Brule from the Department of Critical Care Medicine, Radboud University Nijmegen Medical Centre for performing the transthoracic echocardiography; and the research nurses from the Department of Critical Care Medicine, Radboud University Nijmegen Medical Centre for assistance during the experiments.

![Figure 4](image1.png)

**Figure 4.** Diaphragm electromyography (EMGdi) and transdiaphragmatic pressure (Pdi) during the first (black) and second loading task (blue) in a subject receiving placebo (A and B) and levosimendan (C and D). Subjects were asked to target 40% of Pdimax. In the subject receiving placebo, there is no change in EMGdi (i.e., neural activation), whereas the subject receiving levosimendan shows decreased neural activation and thus increased neuromechanical efficiency of the diaphragm.

![Figure 5](image2.png)

**Figure 5.** Neuromechanical efficiency of the diaphragm (Pdi/EMGdi) before, during (at 1, 3, 6, and 9 min) and after the first and second loading task in the placebo (A) and levosimendan (B) groups. Administration of levosimendan resulted in an increase in diaphragm efficiency ($P < 0.05$) during loaded and unloaded breathing, whereas placebo had no effect on diaphragm efficiency. Data are presented as mean ± SEM (placebo, $n = 13$; levosimendan, $n = 14$).
References


